Bausch & Lomb Corp (BLCO) SEC Filings & Earnings Calls

Leadership uncertainty with interim CEO from parent company may signal integration or governance challenges.

“Interim CEO appointed; CEO departure mutually agreed.”

Tariff policy uncertainty could impact guidance and operations

“Guidance does not take into consideration any changes in tariff policy, given the dynamic nature of the situation” · word for word

Clinical trial for enVista Beyond IOL narrowly missed some endpoints, may delay regulatory submission

“Narrowly missed predefined performance targets related to depth of focus and intermediate visual performance”

Tariff Exposure

“the recent Presidential proclamation which imposes a one hundred percent (100%) tariff on patented pharmaceutical products and associated pharmaceutical ingredients, subject to certain exemptions for certain countries and certain companies.” · word for word

Generic Competition / Loss of Exclusivity

“Following a loss of exclusivity (“LOE”) of and/or generic competition for a product, we would anticipate that product sales for such product would decrease significantly shortly following the LOE or entry of a generic competitor.” · word for word

FDA Regulatory Action

“In June 2026, following a routine FDA inspection of our Tampa, Florida facility, as part of its findings, the FDA issued an Official Action Indicated (“OAI”) of our Tampa, Florida facility.” · word for word

Global Minimum Tax Risk

“The Company expects that there is risk that the impact of the global minimum tax and other changes in tax law in jurisdictions in which it operates may eventually result in an increase to its overall effective tax rate.” · word for word

Generic competition for key products

“Our revenues from PreserVision ® products for 2025 and 2024 accounted for approximately 6% of our total revenues for each period.” · word for word

Tariff exposure on pharmaceutical products

“the recent Presidential Proclamation which imposes a one hundred percent (100%) tariff on patented pharmaceutical products and associated pharmaceutical ingredients” · word for word

Geopolitical conflict in the Middle East

“Our revenues attributable to the impacted regions for the three months ended March 31, 2026 and year ended December 31, 2025 were less than 2% of our total revenues in each period.” · word for word

High leverage and debt service costs

“Interest expense was $97 million and $94 million for the three months ended March 31, 2026 and 2025, respectively, an increase of $3 million” · word for word

Global minimum tax rate risk

“The Company expects that there is risk that the impact of the global minimum tax and other changes in tax law in jurisdictions in which it operates may eventually result in an increase to its overall effective tax rate.” · word for word

Tariff policy uncertainty could impact future performance; guidance explicitly excludes tariff changes.

“This guidance does not take into consideration any changes in tariff policy, given the dynamic nature of the situation.” · word for word

Controlling shareholder concentration risk

“Bausch Health Companies Inc. ... 310,449,643 (2) 87.11 │ %”

BHC spin-off dependency risk

“if BHC's spin-off distribution of B+L Common Shares does not occur prior to the date that is 120 calendar days before the first day of the applicable “TSR Measurement Start Date” ... then in the case of the 2023, 2024, 2025, and 2026 rTSR Annual PSUs, the applicable rTSR performance metric will be deemed achieved at the target performance level (100%).” · word for word

GAAP net loss and negative profitability

“GAAP NET INCOME/(LOSS) ($360M)” · word for word

Voluntary recall in surgical business

“the actual achievement of the Organic Revenue Growth (non-GAAP) performance metric for 2025 was adjusted in accordance with the terms of the award to exclude the effects of the Company’s voluntary recall of intraocular lenses on March 27, 2025.” · word for word

Foreign exchange and tariff exposure

“our Talent and Compensation Committee reviewed and approved certain adjustments to the previously reported results for FY 2025 Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) and FY 2025 Revenues metrics for purposes of the 2025 AIP relating to certain external factors outside of management’s control (i.e., foreign exchange, tariffs, voluntary recall in ” · word for word

GAAP net loss continues despite revenue growth

“GAAP Net Loss of $58M in Q4 and $360M for FY2025”

Voluntary recall of certain enVista IOL products

“Voluntary recall of certain enVista IOL products partially offset Surgical segment growth”

Decline in U.S. Generics business

“Full year 2025 Pharmaceuticals growth partially offset by decline in U.S. Generics business”

Product recall impact

“The unfavorable change was driven by the overall impact of the voluntary recall of certain enVista IOL products and tariffs.” · word for word

High leverage and interest expense

“Interest expense was $421 million and $399 million for 2025 and 2024, respectively, an increase of $22 million.” · word for word

Gross-to-net pricing pressure

“The increase included: (i) an increase in volumes of $172 million and (ii) the favorable impact of foreign currencies of $8 million, partially offset by a decrease in net realized pricing of $104 million.” · word for word

GAAP net loss increased to $28M from net income of $4M, driven by higher income tax provision.

“Net loss attributable to Bausch + Lomb Corporation for Q3 2025 was $28 million, as compared to net income of $4 million for Q3 2024. The change was primarily due to an increase in income tax provision.”

Cash flow from operations decreased to $137M from $154M, impacted by business transformation payments.

“Cash flow from operations for Q3 2025 was $137 million, as compared to $154 million for Q3 2024, a decrease of $17 million. The change was driven by the increase in operating results, offset by business transformation payments.”

Generic competition for Lumify and PreserVision

“settlement was reached with DRL ... providing for, among other things, a market entry date of June 30, 2027 (or earlier subject to certain acceleration clauses) for DRL's generic drops.”

Gross margin pressure from product mix and recall

“Cost of goods sold as a percentage of Product sales was 39.9% and 38.9% for the three months ended September 30, 2025 and 2024, respectively.” · word for word

High leverage and interest expense

“Interest expense was $323 million and $301 million for the nine months ended September 30, 2025 and 2024, respectively, an increase of $22 million.” · word for word

Tariff and trade policy uncertainty

“The Company is monitoring ongoing policy changes being made by the Trump administration, including those related to existing trade agreements and imposition and implementation of new tariffs.” · word for word